Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A two-stage design for bridging studies.

Chin-Fu Hsiao1, Jia-Zhen Xu, Jen-Pei Liu

  • 1National Health Research Institutes, Taipei, Taiwan.

Journal of Biopharmaceutical Statistics
|February 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry study.

Experimental and therapeutic medicine·2026
Same author

Identifying expression and DNA methylation biomarkers for lung adenocarcinoma risk in East Asia.

Journal of the National Cancer Institute·2026
Same author

SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).

European journal of cancer (Oxford, England : 1990)·2026
Same author

Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers.

Journal of the National Cancer Institute·2025
Same author

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration.

Journal of hepatology·2025
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study proposes a two-stage approach for bridging studies, ensuring internal validity and minimizing data duplication. This method allows for reliable extrapolation of foreign clinical data to new regions.

Area of Science:

  • Clinical Pharmacology
  • Regulatory Science
  • Biostatistics

Background:

  • Bridging studies, as defined by ICH E5, supplement foreign clinical data for new regions.
  • Current evaluation methods face challenges with cross-study comparisons and internal validity.
  • Bias can arise from non-internally valid studies, impacting data extrapolation.

Purpose of the Study:

  • To propose a novel two-stage design for bridging studies.
  • To enhance the internal validity of bridging studies.
  • To minimize redundant clinical data collection as per ICH E5 guidelines.

Main Methods:

  • A two-stage adaptive design where the bridging study acts as a second-stage substudy.
  • Enrollment in the substudy is contingent on statistically significant positive treatment effects from the original region's data.

Related Experiment Videos

  • Methods for sample size determination and critical value calculation for each stage are presented.

    • Main Results:

    • The proposed two-stage approach addresses internal validity concerns in bridging studies.
    • This design effectively minimizes unnecessary duplication of clinical data.
    • Statistical methods for sample size and critical values are provided for regional and overall trial analysis.

    Conclusions:

    • The proposed two-stage design offers a robust framework for conducting valid bridging studies.
    • This approach facilitates reliable extrapolation of clinical data across regions while adhering to regulatory guidelines.
    • The methodology supports efficient and statistically sound drug development programs.